Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Oral Maxillofac Surg ; 45(3): 359-67, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26792147

RESUMO

Opinions regarding the treatment of multicystic ameloblastoma are divergent due to its benign nature and the high rate of recurrence if not adequately excised. The aim of the present study was to perform a systematic review of the literature for a qualitative and quantitative assessment of studies addressing primary multicystic ameloblastoma with regard to treatment and recurrence. Searches were conducted of the Ovid Medline and Embase databases for articles published up to January 2014. Based on predefined eligibility criteria, studies were selected in a two-stage screening process conducted by two independent reviewers. Quality assessment of the selected articles was performed using the modified criteria of the Agency for Healthcare Research and Quality. The meta-analysis was performed using Review Manager (RevMan) software. Statistical heterogeneity was investigated by performing a χ(2) test at the 5% significance level (P<0.05) and determining I(2). The relative risk of recurrence was 3.15-fold greater (95% confidence interval 1.98-5.00) when conservative treatment was performed on primary multicystic ameloblastoma in comparison to radical treatment (P<0.00001 for treatment effect; I(2)=0% and P=0.48 for heterogeneity). The findings justify the treatment of primary multicystic ameloblastoma with bone resection.


Assuntos
Ameloblastoma/terapia , Neoplasias Maxilomandibulares/terapia , Recidiva Local de Neoplasia , Ameloblastoma/epidemiologia , Ameloblastoma/patologia , Humanos , Neoplasias Maxilomandibulares/epidemiologia , Neoplasias Maxilomandibulares/patologia , Fatores de Risco , Estados Unidos/epidemiologia
2.
J Dent Res ; 92(10): 868-75, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23955159

RESUMO

Aggressive periodontitis (AgP) is thought to have a faster rate of progression than chronic periodontitis (CP). However, there is a lack of studies systematically investigating disease progression and tooth loss in AgP. A systematic search of the literature was conducted by two independent reviewers for longitudinal studies including patients with AgP (previously known as 'periodontosis', 'juvenile' or 'early-onset' periodontitis) indicating measures of disease progression. Ovid MEDLINE(®) and Embase databases were searched for at least 5-year longitudinal human studies in AgP patients. In total, 16 studies were included in the review, from an initial search of 1,601 titles. Heterogeneity was detected for disease definition and clinical data reporting; hence meta-analysis was feasible only for the objective measure 'tooth loss'. The average tooth loss for all AgP cases was 0.09 (95% C.I. = 0.06-0.16) per patient-year. The corresponding values by diagnosis were 0.05, 0.14, and 0.12 tooth loss per patient-year, respectively, for LAgP, GAgP, and un-specified AgP. For studies reporting tooth loss during the 'observational period' (excluding extractions at initial therapy), the average tooth loss for AgP was 0.09 per patient-year. High heterogeneity was detected for these analyses. In conclusion, most studies report good long-term stability of treated AgP cases.


Assuntos
Periodontite Agressiva/fisiopatologia , Perda de Dente/etiologia , Periodontite Agressiva/complicações , Periodontite Agressiva/terapia , Perda do Osso Alveolar/etiologia , Progressão da Doença , Humanos
3.
Int J Oral Maxillofac Surg ; 41(12): 1566-70, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22727360

RESUMO

This study reports the case of a patient with a severely resorbed mandible who was treated without a bone graft, using short implants, internal rigid fixation, rhBMP-2 and ß-tricalcium phosphate. A 76-year-old woman, with a severely resorbed mandible (less than 3mm), reported a history of nearly 25 years of complete edentulism and consecutive treatment failures, with total bilateral exposed inferior alveolar nerves and complete bone resorption of the inferior border in some areas. The treatment of choice was the placement of a 2.0mm thick unilock bone plate (MatrixMandible, Synthes Maxillofacial, Paoli, PA, USA), to reinforce the mandible. Eight short implants with a regular platform (Nobel Biocare, Goteborg, Sweden) were placed: three on the external oblique line on both sides and two on the symphysis. In order to augment mandible height and coat the exposed thread of the anterior implants, rhBMP-2 (Infuse Bone, Meditronic Sofamor Danek, Memphis, TN, USA) and ß-tricalcium phosphate (Cerasorb; Curasan, Kleinostheim, Germany) were used. Four 1.3 mmL miniplates were placed to support the graft. 14 months after surgery, the patient was satisfied and had excellent function without complications.


Assuntos
Proteína Morfogenética Óssea 2/uso terapêutico , Doenças Mandibulares/tratamento farmacológico , Idoso , Proteína Morfogenética Óssea 2/administração & dosagem , Implantes Dentários , Feminino , Humanos , Doenças Mandibulares/patologia , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...